Cargando…

Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study

BACKGROUND: OnabotulinumtoxinA is effective in preventing chronic migraine (CM); however, the benefit of onabotulinumtoxinA in patients with CM with daily headache is unknown because these patients are typically excluded from clinical trials. This subanalysis of the COMPEL Study assessed the efficac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Young, William B., Ivan Lopez, J., Rothrock, John F., Orejudos, Amelia, Manack Adams, Aubrey, Lipton, Richard B., Blumenfeld, Andrew M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734507/ https://www.ncbi.nlm.nih.gov/pubmed/30709333 http://dx.doi.org/10.1186/s10194-018-0953-0

Ejemplares similares

Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study
por: Young, William B., et al.
Publicado: (2019)

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
por: Blumenfeld, Andrew M., et al.
Publicado: (2018)

Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
por: Winner, Paul K., et al.
Publicado: (2019)

FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
por: Rothrock, John F., et al.
Publicado: (2019)

Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety
por: Blumenfeld, Andrew M, et al.
Publicado: (2019)

Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine
por: Blumenfeld, Andrew M., et al.
Publicado: (2020)

Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
por: Burstein, Rami, et al.
Publicado: (2020)

The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine
por: Silberstein, Stephen D., et al.
Publicado: (2020)

Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis
por: Matharu, Manjit, et al.
Publicado: (2017)

OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients
por: Gfrerer, Lisa, et al.
Publicado: (2021)

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014)

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
por: Manack Adams, Aubrey, et al.
Publicado: (2023)

Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine
por: Blumenfeld, Andrew M., et al.
Publicado: (2015)

Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
por: Mechtler, Laszlo, et al.
Publicado: (2022)

Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine
por: Winner, Paul K., et al.
Publicado: (2020)

Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Turkel, Catherine C., et al.
Publicado: (2023)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

Daily Headache in Chronic Migraine Is a Predictive Factor of Response in Patients Who Had Completed Three Sessions of OnabotulinumtoxinA
por: Martínez-Pías, Enrique, et al.
Publicado: (2021)

OnabotulinumtoxinA in the treatment of refractory chronic cluster headache
por: Lampl, Christian, et al.
Publicado: (2018)

Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA
por: Torres-Ferrus, Marta, et al.
Publicado: (2020)

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Russell, Michael Bjørn
Publicado: (2011)

OnabotulinumtoxinA for chronic migraine: a critical appraisal
por: Gooriah, Rubesh, et al.
Publicado: (2015)

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

Prediction of patient's response to OnabotulinumtoxinA treatment for migraine
por: Parrales Bravo, Franklin, et al.
Publicado: (2019)

Adult Abdominal Migraine Improved by OnabotulinumtoxinA Injections
por: Hermanowicz, Neal
Publicado: (2021)

OnabotulinumtoxinA in chronic migraine: is the response dose dependent?
por: Zandieh, Ali, et al.
Publicado: (2022)

Safety of OnabotulinumtoxinA in the [management of] chronic migraine in pregnancy
por: Smirnoff, Liza
Publicado: (2022)

Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine
por: Ailani, Jessica, et al.
Publicado: (2021)

Response to “Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice”
por: Blumenfeld, Andrew M., et al.
Publicado: (2020)

Combined onabotulinumtoxinA/atogepant treatment blocks activation/sensitization of high-threshold and wide-dynamic range neurons
por: Melo-Carrillo, Agustin, et al.
Publicado: (2020)

Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation
por: Bendtsen, Lars, et al.
Publicado: (2018)

OnabotulinumtoxinA Treatment in Chronic Migraine: Investigation of Its Effects on Disability, Headache and Neck Pain Intensity
por: Onan, Dilara, et al.
Publicado: (2022)

Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Aurora, Sheena, et al.
Publicado: (2011)

Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans
por: Byun, Jung-Ick, et al.
Publicado: (2017)

Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use
por: Frampton, James E.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_33dlu7vkn2qnbh4mvmri1nsdef